Playback speed
10 seconds
Zodasiran Silences Hepatic ANGPTL3 Leading to Deep and Durable Reduction in Atherogenic Lipids and Lipoproteins in Mixed Dyslipidemia Patients - Final Results from ARCHES-2 Trial
189 views
June 6, 2024
Chapters
Introduction & Background on Angiopoietin-like 3
00:00
ARCHES-2 Trial Design & Objectives
02:27
Study Population Characteristics
04:49
Efficacy Results & Lipid Profile Improvements
05:58
Safety Profile & Summary of Findings
07:33
Comments 1
Login to view comments.
Click here to Login
Related Videos
AUTOPLAY